CohBar, Inc.
1455 Adams Drive
Suite 2050
Menlo Park
California
94025
United States
91 articles with CohBar, Inc.
-
CohBar to Present at the BIO 2021 Digital Conference
6/10/2021
CohBar, Inc. today announced its Chief Executive Officer Dr. Joseph Sarret will present a corporate overview at the BIO 2021 Digital Conference, to be held on June 14 - 18, 2021.
-
CohBar Reports First Quarter 2021 Financial Results and Provides Business UpdateCompany to host conference call at 5:00 p.m. ET
5/17/2021
CohBar, Inc., a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, reported its financial results for the first quarter ended March 31, 2021.
-
CohBar to Announce 2021 First Quarter Financial Results and Provide Business Update on May 17, 2021Company to host conference call and webcast at 5:00 p.m. ET
5/3/2021
CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that the company will release its first quarter 2021 financial results after the market closes on Monday, May 17, 2021.
-
CohBar Appoints Joseph J. Sarret, M.D., J.D. as Chief Executive Officer and DirectorAnnounces change to the Board of Director’s Chair
4/27/2021
CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced the appointment of Joseph J. Sarret, M.D., J.D. as Chief Executive Officer and Director, effective May 3, 2021.
-
CohBar Completes Last Subject Visit in the Phase 1b Clinical Trial for CB4211 Under Development for NASH and Obesity
4/21/2021
CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced that the last subject has completed their final visit in the Phase 1b stage of the CB4211 clinical study for nonalcoholic steatohepatitis (NASH) and obesity
-
CohBar to Present at the Mitochondria-Targeted Drug Development Summit
4/14/2021
CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that its Chief Executive Officer Steven Engle will present at the Mitochondria-Targeted Drug Development Summit being held virtually on April 27 - 29, 2021.
-
CohBar Reports Fourth Quarter 2020 Financial Results and Provides Business UpdateCompany to host conference call and webcast at 5:00 p.m. ET
3/30/2021
CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today reported its financial results for the fourth quarter ended December 31, 2020.
-
CohBar Completes Enrollment in the Phase 1b Clinical Trial for CB4211 Under Development for NASH and Obesity
3/29/2021
CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced the completion of enrollment in the Phase 1b stage of the CB4211 clinical study for nonalcoholic steatohepatitis (NASH) and obesity.
-
CohBar to Participate in M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference
3/12/2021
CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that CEO Steven Engle will participate in a fireside chat with Research Analyst Jason McCarthy at the Inaugural Emerging Growth Conference presented by M Vest LLC and Maxim Group LLC.
-
CohBar to Present at the 33rd Annual ROTH Conference
3/2/2021
CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that its Chief Executive Officer, Steven Engle, will participate in a fireside chat with ROTH Senior Research Analyst Elemer Piros, Ph.D. at the 33 rd Annual ROTH Conference, being held virtually March 15 – 17, 2021. 33 rd Annual ROTH Conference
-
CohBar to Present at the H.C. Wainwright Global Life Sciences Conference
2/25/2021
CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that its Chief Executive Officer, Steven Engle, will present a company overview at the H.C. Wainwright Global Life Sciences Conference, being held virtually March 9 – 10, 2021.
-
CohBar, Inc. is pioneering mitochondrial-based therapies with a candidate in a Phase Ia/Ib clinical trial as a potential treatment for nonalcoholic steatohepatitis (NASH) and obesity, where top-line results are expected later this year.
-
CohBar to Present at the BIO CEO & Investor Digital Conference
2/9/2021
CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that its Chief Executive Officer, Steven Engle, will present a company overview at the BIO CEO & Investor Digital Conference, being held virtually on February 16 - 18, 2021
-
CohBar to Present at the 3rd Annual Longevity Therapeutics Conference
1/20/2021
CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that its Chief Executive Officer, Steven Engle, will present a company overview at the 3rd Annual Longevity Therapeutics Conference, being held virtually on January 26 - 28, 2021.
-
CohBar Announces Preclinical Collaboration with NIAID to Evaluate Potential of CB5064 Analogs for Treatment of COVID-19 ARDS
1/11/2021
CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced it has signed a Non-Clinical Evaluation Agreement (NCEA) with the National Institute of Allergy and Infectious Diseases (NIAID) to evaluate the potential of CB5064 Analogs for the treatment of COVID-19 associated Acute Respiratory Distress Syndrome (ARDS).
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for December 15, 2020.
-
CohBar Confirms Efficacy of Novel Apelin Agonists in Acute Respiratory Distress Syndrome (ARDS) Model
12/9/2020
CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced new preclinical data confirming the efficacy of its apelin agonist peptides in a preclinical model of acute respiratory distress syndrome (ARDS). The company expects the apelin agonists to have potential to treat COVID-19 associated ARDS as well as ARDS patients
-
CohBar to Present at the Piper Sandler 32nd Annual Healthcare Conference
11/19/2020
CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that its Chief Executive Officer, Steven Engle, will present a company overview at the Piper Sandler 32 nd Annual Healthcare Conference, being held virtually on December 1 - 3, 2020. This presentation will be available on demand for registered attendees. Abo
-
CohBar to Announce 2020 Third Quarter Financial Results and Provide Business Update on November 16, 2020Company to host conference call and webcast at 5:00 p.m. ET
11/2/2020
CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that the company will release its third quarter 2020 financial results after the market closes on Monday, November 16, 2020. Management will host a conference call with a slide presentation at 5:00 p.m. ET (2:00 p.m. PT) on the same day to provide an update on t
-
CohBar to Host Key Opinion Leader Meeting on Antifibrotic Peptides for the Potential Treatment of Idiopathic Pulmonary Fibrosis
10/29/2020
CohBar, Inc. announced it will host a Key Opinion Leader webinar on the current treatment landscape in idiopathic pulmonary fibrosis, the unmet medical need, and positive findings from preclinical studies of its CB5138 Analogs on Friday, November 6 at 2:00pm ET.